digiM Launches miQ3: A Microstructure Equivalence Database

digiM Launches miQ3: A Microstructure Equivalence Database of Reference Listed Drugs

digiM is proud to announce the launch of miQ3 (Microstructure Q3 Equivalence Database), a groundbreaking resource dedicated to cataloging the microstructural attributes of reference listed drugs (RLDs).

For over a decade, digiM has been at the forefront of microstructure science, studying thousands of pharmaceutical samples and developing industry-leading techniques for 2D and 3D imaging analysis. Now, we are bringing that expertise together in a single, powerful database.

The initial release of miQ3 includes data on more than 40 products across six dosage forms, with more being added regularly. Each data package captures detailed microstructure properties derived from digiM’s best-in-class characterization technologies and analytical workflows.

With miQ3, researchers can access rich microstructure data for a fraction of the cost and time required to source RLDs and perform analyses independently. This means critical microstructure information can now inform formulation development from the earliest stages.

All analyses included in miQ3 are part of digiM’s standard analytical service portfolio and are powered by our proprietary I2S platform. Additionally, for a deeper level of insight, digiM offers the option to replicate any miQ3 dataset on a new formulation to enable direct microstructure comparison.

The development of miQ3 was initiated and supported by digiM's IDIQ contract with the FDA, which aims to support regulatory assessment of complex drug products and guideline development.

miQ3 data packages are available today for purchase individually or through a subscription license for full database access.

For more information or to purchase access to miQ3, please contact us at info@digimsolution.com